Clinical Trials

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06520098 2025-10-14

Benefit VA

Phase 2 Recruiting

100 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04446962 2025-09-25

LOC-R01

118 enrolled

CNSLymphoid

Lymphoma, Neurologic Manifestations, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms

NCT02956382 2025-07-18

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

24 enrolled 18 charts

Lymphoma, Lymphoma, Follicular, Recurrence

NCT01974440 2025-05-25

SELENE

403 enrolled 23 charts

Phase EARLY_PHASE1 Completed

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT03295240 2025-05-13

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

10 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT01855750 2025-02-04

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

838 enrolled 16 charts

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02733042 2023-11-18

FUSION NHL 001

106 enrolled 48 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02352558 2023-11-14

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Phase 1 Completed

15 enrolled

Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT02760485 2023-06-15

A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

33 enrolled 20 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05431179 2023-04-21

A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 3 Withdrawn

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT03876028 2023-01-31

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Phase 1 Terminated

10 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02756247 2022-10-10

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Phase 1 Completed

37 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02356458 2022-03-11

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

Phase 1/2 Terminated

58 enrolled

Lymphoma, Neoplasms, Recurrence, Lymphoma, Mantle-Cell

NCT02165397 2021-03-03

Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

181 enrolled 20 charts

Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia

NCT01578707 2019-12-18

RESONATE™

391 enrolled 14 charts

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01980654 2019-04-16

Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

Phase 2 Completed

80 enrolled 14 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT02269085 2019-02-28

Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma

Phase 1 Terminated

8 enrolled

Lymphoma, Recurrence, Lymphoma, Mantle-Cell

NCT02142049 2019-02-05

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

35 enrolled 18 charts

Lymphoma

NCT02272686 2018-12-05

Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma

Phase 2 Terminated

1 enrolled 5 charts

Lymphoma, Lymphoma, B-Cell

NCT01779791 2017-07-18

A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma

Phase 2 Completed

110 enrolled

Lymphoma, Lymphoma, Follicular

NCT02780830 2016-09-15

INHIBITOR

Phase 1 Withdrawn

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01236391 2015-08-28

PCYC-1104-CA

Phase 2 Completed

115 enrolled 11 charts

Lymphoma, Lymphoma, Mantle-Cell

NCT00849654 2013-05-22

PCYC-04753

Phase 1 Completed

66 enrolled